Deena Beasley/Julie Steenhuysen
路透6月18日 - 美国食品和药物管理局周三批准了吉利德科学公司(Gilead Sciences)的GILD.O来那卡韦(lenacapavir),该药每年注射两次,用于预防成人和青少年的艾滋病感染。 吉利德公司称,该药将以Yeztugo的品牌名称销售。
(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.